Trials / Recruiting
RecruitingNCT06696014
Mirikizumab Real World Protocol
MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- University of North Carolina, Chapel Hill · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.
Conditions
Timeline
- Start date
- 2025-05-08
- Primary completion
- 2030-01-01
- Completion
- 2030-01-01
- First posted
- 2024-11-19
- Last updated
- 2025-07-09
Locations
9 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT06696014. Inclusion in this directory is not an endorsement.